公司研发平台部执行总监王涛博士于2025年9月18日获民主选举为第二届监事会职工代表监事。王涛博 士的任期自2025年9月18日起生效，并将于第二届监事会结束时届满。 智通财经APP讯，友芝友生物-B(02496)发布公告，张敬先生因个人职业发展原因而辞去公司职工代表监 事职务，自2025年9月18日起生效。 ...

Core Viewpoint - Youzhiyou Biotechnology-B (02496.HK) announced the resignation of Zhang Jing from the position of employee representative supervisor due to personal career development reasons, effective September 18, 2025 [1] Group 1 - Zhang Jing's resignation is attributed to personal career development [1] - Wang Tao, the Executive Director of the R&D Platform Department, has been democratically elected as the employee representative supervisor of the second supervisory board, effective September 18, 2025 [1]

（於中華人民共和國註冊成立的股份有限公司） （股份代號：2496） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 WUHAN YZY BIOPHARMA CO., LTD. 武漢友芝友生物製藥股份有限公司 王博士的任期自2025年9月18日起生效，並將於第二屆監事會結束時屆滿。王博 士將不會作為職工代表監事自本公司收取任何酬金。 職工代表監事變更 監事辭任 武漢友芝友生物製藥股份有限公司（「本公司」，連同其附屬公司，統稱「本集團」） 董事會（「董事會」）謹此宣佈，張敬先生（「張先生」）因個人職業發展原因而辭去 本公司職工代表監事職務，自2025年9月18日起生效。 張先生已確認，彼與本公司董事會及監事會（「監事會」）並無意見分歧，且無任何 與其辭任相關的事項需提請本公司股東（「股東」）或香港聯合交易所有限公司垂 注。 本公司謹藉此機會衷心感謝張先生於其任職期間為本公司所作的貢獻。 委任監事 董事會欣然宣佈，本公司研發平台部執行總監王濤博士（「王博士 ...

Financial Performance - Revenue for the six months ended June 30, 2025, was RMB 37,187,000, compared to no revenue in the same period of 2024[11] - Gross profit for the period was RMB 7,669,000, with a cost of revenue of RMB 29,518,000[11] - Other income increased to RMB 7,684,000 from RMB 4,786,000 year-over-year[11] - The company reported a pre-tax loss of RMB 58,834,000, an improvement from a loss of RMB 78,396,000 in the same period last year[11] - The total loss and comprehensive expenses for the reporting period were RMB 58.8 million, a reduction of RMB 19.6 million compared to RMB 78.4 million in the previous year[51] - The company’s basic and diluted loss per share for the period was RMB (0.30), improved from RMB (0.40) in the same period of 2024[117] - The net loss for the period was RMB (58,834,000), an improvement from a net loss of RMB (78,396,000) in the prior year[117] Research and Development - Research and development expenses decreased to RMB 60,186,000 from RMB 70,290,000 in the previous year[11] - The company is focused on developing bispecific antibody therapies targeting various therapeutic areas, including oncology and autoimmune diseases[12] - Multiple proprietary research and development platforms, such as Y-BODY® and Nano-Ybody®, are being actively constructed to advance candidate molecules into clinical stages[12] - The company has three clinical-stage candidates focused on tumor treatment, including M701 and Y101D, with M701 targeting EpCAM and CD3 for malignant ascites (MA) and malignant pleural effusion (MPE) treatment[13] - M701's Phase III trial for MA has enrolled 312 patients, with the trial showing good safety and efficacy results[22] - The Phase II trial for MPE has completed 93% of patient enrollment, demonstrating significant potential in controlling MPE in NSCLC patients[23] - Y101D, a recombinant BsAb targeting PD-L1 and TGF-β, has completed its Phase I trial for metastatic or locally advanced solid tumors, with the Ib/II trial for pancreatic cancer ongoing[24] - Y332, targeting VEGF and TGF-β, has initiated its Phase I trial, enrolling 18 patients, and showing good overall safety[25] - The company plans to accelerate the overseas development of its core pipeline and expedite the clinical development of candidate drugs, with specific goals including obtaining IND approval for M701 in the U.S. and completing various clinical trials for Y225, Y101D, and Y332[35] Assets and Liabilities - Non-current assets as of June 30, 2025, were valued at RMB 44,332,000, down from RMB 46,508,000 at the end of 2024[11] - Current assets decreased to RMB 195,295,000 from RMB 221,335,000[11] - Total liabilities increased to RMB 267,072,000 from RMB 237,308,000, resulting in a net asset value of RMB (27,445,000)[11] - Cash and cash equivalents increased from RMB 126.3 million as of December 31, 2024, to RMB 166.2 million as of June 30, 2025, due to improved cash flows from operating and financing activities[52] - As of June 30, 2025, bank borrowings amounted to RMB 156.4 million, up from RMB 126.9 million at the end of 2024, due to additional loans for working capital[56] Employee and Management - The group has a total of 106 employees as of June 30, 2025, including 82 R&D personnel and 24 general and administrative staff[65] - Employee compensation includes year-end bonuses, communication, transportation, and meal subsidies, as well as paid leave and holiday benefits[65] - The company is committed to providing competitive compensation and ensuring a safe working environment for employees[65] - The company incurred RMB 3,300,000 in salaries and other benefits for key management personnel for the six months ended June 30, 2025, an increase from RMB 3,094,000 in 2024[174] - The discretionary bonuses for key management personnel decreased to RMB 36,000 in 2025 from RMB 338,000 in 2024[174] Shareholder Structure - The total issued shares consist of 82,380,386 non-listed shares and 111,468,814 H-shares[72] - Dr. Yuan Qian holds 54,262,305 non-listed shares, representing 27.99% of the company, and 1,342,600 H shares, representing 0.69%[70] - The major shareholder, Shiyao Group, controls 51,241,785 H-shares, which is 26.43% of the total equity[75] - The company has a significant stake in Chengdu Puhua Kaizhi Biotechnology Co., Ltd., with 50% ownership indirectly held by Dr. Yuan Qian[72] - The company has a complex ownership structure involving multiple layers of partnerships and holdings, indicating a diversified investment approach[84] Financial Management - The company has not made any arrangements for directors or supervisors to benefit from acquiring shares or debt securities during the reporting period[83] - The company did not repurchase, sell, or redeem any of its listed securities during the reporting period[106] - The board does not recommend the distribution of an interim dividend for the reporting period[115] - The audit committee has reviewed the unaudited interim financial information and found it compliant with relevant accounting standards and regulations[114] Future Plans and Strategies - The company aims to leverage commercialization licensing and international collaborations to drive the marketization of core products, establishing a solid foundation for future market positioning[34] - The company plans to complete the production process characterization study for M701 and conduct process validation in preparation for commercial launch[35] - The company has not disclosed any new strategies or product developments in the provided documents[82]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 武漢友芝友生物製藥股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 3. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | 於香港聯交所上市 (註1) | 否 | | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上市外資股 | | | 第 1 頁 共 11 頁 v 1.1.1 FF301 FF301 | | 法定/註冊股份數目 | 面值 | | 法定/註冊股本 | | | --- | --- | --- | --- | --- | --- | | 上月底結存 | | 6,869,744 RMB | 1 RMB | | 6,869,744 | | 增加 / 減少 (-) | | 0 | RMB | | 0 | | 本月底結存 | | 6,869,744 RMB | 1 RMB ...

Group 1 - The core viewpoint of the article highlights that *ST Huifeng (002496) has experienced revenue growth but significant profit decline in its 2025 mid-year report, indicating a challenging financial situation [1] - The company's total operating revenue reached 157 million yuan, a year-on-year increase of 42.6%, while the net profit attributable to shareholders was 11.47 million yuan, a year-on-year decrease of 67.02% [1] - The gross profit margin was reported at 10.01%, down 65.83% year-on-year, and the net profit margin was 5.58%, down 82.21% year-on-year, reflecting deteriorating profitability [1] Group 2 - The company reported a significant increase in sales expenses, management expenses, and financial expenses totaling 57.27 million yuan, which accounted for 36.47% of revenue, a decrease of 42.54% year-on-year [1] - The earnings per share (EPS) decreased to 0.01 yuan, down 67.1% year-on-year, indicating a decline in shareholder returns [1] - The company's historical financial performance has been poor, with a median return on invested capital (ROIC) of -8.51% over the past decade, and a particularly low ROIC of -23.34% in 2023 [3]

Group 1 - The core point of the article is that *ST Huifeng (002496.SZ) released its semi-annual report for 2025, indicating the current status of institutional ownership [1] - As of August 26, 2025, there is one institutional investor holding shares in *ST Huifeng, with a total holding of 30.5953 million shares, representing 2.03% of the total share capital [1] - The institutional investor includes Jiangsu Huifeng Biological Agriculture Co., Ltd. - Phase I Employee Stock Ownership Plan, maintaining the same holding percentage [1]

智通财经APP讯，友芝友生物-B(02496)发布截至2025年6月30日止六个月业绩，收入3718.7万元(人民 币，下同);净亏损5883.4万元，同比收窄25%;每股基本亏损0.30元。 于报告期内，收入包括：许可费收入及研发服务收入。许可费收入主要是公司与正大天晴签订了一项许 可合作协定。截至2025年6月30日止六个月，集团就授予许可使用权以实现发展里程碑确认收入470万 元。 研发服务收入主要是依据公司与正大天晴签订的许可合作协定，公司为其提供委托研发服务。在截至 2025年6月30日止六个月，公司根据满足履约义务所付出的努力或投入与预计为满足该履约义务所需的 总投入之间的相对比例按进度确认了3250万元的研发服务收入。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 WUHAN YZY BIOPHARMA CO., LTD. 武漢友芝友生物製藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2496） 截至2025年6月30日止六個月的中期業績公告 武漢友芝友生物製藥股份有限公司（「本公司」，連同其附屬公司，「本集團」）的董 事（「董事」）會（「董事會」）欣然宣佈本集團截至2025年6月30日止六個月（「報告 期」）的未經審計綜合中期業績，連同截至2024年6月30日止六個月（「同期」）的比 較數字。 於本公告中，「我們」及「我們的」指本公司及（如文義另有所指）本集團。本公告 所載若干金額及百分比數字已進行約整或約整至小數點後一位或兩位（如適用）。 任何表格、圖表或其他地方所列總額及數額總和的任何差異乃由於四捨五入所致。 1 財務摘要 | | 截至6月30日止六個月 | | | --- | --- | --- | | | 2025年 | 202 ...

格隆汇8月14日丨友芝友生物-B(02496.HK)公布，公司将于2025年8月26日召开董事会会议，以（其中包 括）审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布。 ...